IMMNC-HF: IntraMyocardial Injection of Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients

Inclusion Criteria: 1. Men and women of any ethnic origin 18 ≤ aged≤ 65 years 2. EF≤40 (by Echocardiography) and regional wall motion abnormality 3. Not responding to standard therapies 4. the New York Heart Association (NYHA) class ≥ III 5. Myocardial infarction due to coronary artery atherosclerotic disease 6. An area of regional dysfunction, i.e., hypokinetic, akinetic, or dyskinetic (echocardiography or MRI) 7. Normal liver and renal function 8. No or controlled diabetes 9. Able to give voluntary written consent and understand the study information provided to him Exclusion Criteria: 1. Participation in another clinical trial within 30 days prior randomisation 2. Previously received stem/progenitor cell therapy 3. Pregnant women 4. Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study or to follow the protocol 5. Cardiogenic shock requiring mechanical support 6. Congenital / valvular heart disease 7. Implantable cardioverter defibrillator (ICD) transplant 8. Platelet count \<100.000/µl, or hemoglobin \<8.5 g/dl 9. Impaired renal function, i.e. creatinine \>2.5 mg/dl 10. Fever or diarrhea within 4 weeks prior screening 11. History of bleeding disorder within 3 months prior screening 12. Uncontrolled hypertension (systolic \>180 mmHg and diastolic \>120 mmHg) or Sustained ventricular arrhythmia 13. Life expectancy of less than two years from any non-cardiac cause or uncontrolled neoplastic disease